Global Rheumatoid Arthritis (RA) Drugs 麻豆原创 Research Report 2024

Publication ID:

PB504245822

Publication Date:

April 26, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Rheumatoid arthritis (RA) is an inflammatory disease that progresses over time affecting the joints. The symptoms aggravate over time, which is why medication for RA becomes essential to stop the inflammation. There is no permanent cure for rheumatoid arthritis, though increasing research activities regarding the same indicate that remission of symptoms is achieved when treatment begins in the initial stages with strong medications known as disease-modifying antirheumatic drugs (DMARDs).
The global Rheumatoid Arthritis (RA) Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Rheumatoid Arthritis (RA) Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Rheumatoid Arthritis (RA) Drugs.
Report Scope
The Rheumatoid Arthritis (RA) Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Rheumatoid Arthritis (RA) Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Rheumatoid Arthritis (RA) Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
AbbVie
Roche
Merck
HEYL Chemisch-pharmazeutische Fabrik
Johnson & Johnson
Amgen, Inc.
Pfizer
Bristol-Myers Squibb
UCB
GSK
Sanofi
Abbott Laboratories
Teva Pharmaceutical
Segment by Type
NSAIDs
Analgesic Drugs
Corticosteroids
DMARDs
Biological Therapies
JAK-inhibitors
Segment by Application
Hospitals
Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Rheumatoid Arthritis (RA) Drugs companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 NSAIDs
1.2.3 Analgesic Drugs
1.2.4 Corticosteroids
1.2.5 DMARDs
1.2.6 Biological Therapies
1.2.7 JAK-inhibitors
1.3 麻豆原创 by Application
1.3.1 Global Rheumatoid Arthritis (RA) Drugs 麻豆原创 Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Rheumatoid Arthritis (RA) Drugs 麻豆原创 Perspective (2019-2030)
2.2 Rheumatoid Arthritis (RA) Drugs Growth Trends by Region
2.2.1 Global Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 Rheumatoid Arthritis (RA) Drugs Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 Rheumatoid Arthritis (RA) Drugs Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 Rheumatoid Arthritis (RA) Drugs 麻豆原创 Dynamics
2.3.1 Rheumatoid Arthritis (RA) Drugs Industry Trends
2.3.2 Rheumatoid Arthritis (RA) Drugs 麻豆原创 Drivers
2.3.3 Rheumatoid Arthritis (RA) Drugs 麻豆原创 Challenges
2.3.4 Rheumatoid Arthritis (RA) Drugs 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Rheumatoid Arthritis (RA) Drugs Players by Revenue
3.1.1 Global Top Rheumatoid Arthritis (RA) Drugs Players by Revenue (2019-2024)
3.1.2 Global Rheumatoid Arthritis (RA) Drugs Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Rheumatoid Arthritis (RA) Drugs 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Rheumatoid Arthritis (RA) Drugs Revenue
3.4 Global Rheumatoid Arthritis (RA) Drugs 麻豆原创 Concentration Ratio
3.4.1 Global Rheumatoid Arthritis (RA) Drugs 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Rheumatoid Arthritis (RA) Drugs Revenue in 2023
3.5 Rheumatoid Arthritis (RA) Drugs Key Players Head office and Area Served
3.6 Key Players Rheumatoid Arthritis (RA) Drugs Product Solution and Service
3.7 Date of Enter into Rheumatoid Arthritis (RA) Drugs 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Rheumatoid Arthritis (RA) Drugs Breakdown Data by Type
4.1 Global Rheumatoid Arthritis (RA) Drugs Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global Rheumatoid Arthritis (RA) Drugs Forecasted 麻豆原创 Size by Type (2025-2030)
5 Rheumatoid Arthritis (RA) Drugs Breakdown Data by Application
5.1 Global Rheumatoid Arthritis (RA) Drugs Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global Rheumatoid Arthritis (RA) Drugs Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size (2019-2030)
6.2 North America Rheumatoid Arthritis (RA) Drugs 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size by Country (2019-2024)
6.4 North America Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size (2019-2030)
7.2 Europe Rheumatoid Arthritis (RA) Drugs 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size by Country (2019-2024)
7.4 Europe Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size (2019-2030)
8.2 Asia-Pacific Rheumatoid Arthritis (RA) Drugs 麻豆原创 Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size by Region (2019-2024)
8.4 Asia-Pacific Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size (2019-2030)
9.2 Latin America Rheumatoid Arthritis (RA) Drugs 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size by Country (2019-2024)
9.4 Latin America Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size (2019-2030)
10.2 Middle East & Africa Rheumatoid Arthritis (RA) Drugs 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size by Country (2019-2024)
10.4 Middle East & Africa Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AbbVie
11.1.1 AbbVie Company Detail
11.1.2 AbbVie Business Overview
11.1.3 AbbVie Rheumatoid Arthritis (RA) Drugs Introduction
11.1.4 AbbVie Revenue in Rheumatoid Arthritis (RA) Drugs Business (2019-2024)
11.1.5 AbbVie Recent Development
11.2 Roche
11.2.1 Roche Company Detail
11.2.2 Roche Business Overview
11.2.3 Roche Rheumatoid Arthritis (RA) Drugs Introduction
11.2.4 Roche Revenue in Rheumatoid Arthritis (RA) Drugs Business (2019-2024)
11.2.5 Roche Recent Development
11.3 Merck
11.3.1 Merck Company Detail
11.3.2 Merck Business Overview
11.3.3 Merck Rheumatoid Arthritis (RA) Drugs Introduction
11.3.4 Merck Revenue in Rheumatoid Arthritis (RA) Drugs Business (2019-2024)
11.3.5 Merck Recent Development
11.4 HEYL Chemisch-pharmazeutische Fabrik
11.4.1 HEYL Chemisch-pharmazeutische Fabrik Company Detail
11.4.2 HEYL Chemisch-pharmazeutische Fabrik Business Overview
11.4.3 HEYL Chemisch-pharmazeutische Fabrik Rheumatoid Arthritis (RA) Drugs Introduction
11.4.4 HEYL Chemisch-pharmazeutische Fabrik Revenue in Rheumatoid Arthritis (RA) Drugs Business (2019-2024)
11.4.5 HEYL Chemisch-pharmazeutische Fabrik Recent Development
11.5 Johnson & Johnson
11.5.1 Johnson & Johnson Company Detail
11.5.2 Johnson & Johnson Business Overview
11.5.3 Johnson & Johnson Rheumatoid Arthritis (RA) Drugs Introduction
11.5.4 Johnson & Johnson Revenue in Rheumatoid Arthritis (RA) Drugs Business (2019-2024)
11.5.5 Johnson & Johnson Recent Development
11.6 Amgen, Inc.
11.6.1 Amgen, Inc. Company Detail
11.6.2 Amgen, Inc. Business Overview
11.6.3 Amgen, Inc. Rheumatoid Arthritis (RA) Drugs Introduction
11.6.4 Amgen, Inc. Revenue in Rheumatoid Arthritis (RA) Drugs Business (2019-2024)
11.6.5 Amgen, Inc. Recent Development
11.7 Pfizer
11.7.1 Pfizer Company Detail
11.7.2 Pfizer Business Overview
11.7.3 Pfizer Rheumatoid Arthritis (RA) Drugs Introduction
11.7.4 Pfizer Revenue in Rheumatoid Arthritis (RA) Drugs Business (2019-2024)
11.7.5 Pfizer Recent Development
11.8 Bristol-Myers Squibb
11.8.1 Bristol-Myers Squibb Company Detail
11.8.2 Bristol-Myers Squibb Business Overview
11.8.3 Bristol-Myers Squibb Rheumatoid Arthritis (RA) Drugs Introduction
11.8.4 Bristol-Myers Squibb Revenue in Rheumatoid Arthritis (RA) Drugs Business (2019-2024)
11.8.5 Bristol-Myers Squibb Recent Development
11.9 UCB
11.9.1 UCB Company Detail
11.9.2 UCB Business Overview
11.9.3 UCB Rheumatoid Arthritis (RA) Drugs Introduction
11.9.4 UCB Revenue in Rheumatoid Arthritis (RA) Drugs Business (2019-2024)
11.9.5 UCB Recent Development
11.10 GSK
11.10.1 GSK Company Detail
11.10.2 GSK Business Overview
11.10.3 GSK Rheumatoid Arthritis (RA) Drugs Introduction
11.10.4 GSK Revenue in Rheumatoid Arthritis (RA) Drugs Business (2019-2024)
11.10.5 GSK Recent Development
11.11 Sanofi
11.11.1 Sanofi Company Detail
11.11.2 Sanofi Business Overview
11.11.3 Sanofi Rheumatoid Arthritis (RA) Drugs Introduction
11.11.4 Sanofi Revenue in Rheumatoid Arthritis (RA) Drugs Business (2019-2024)
11.11.5 Sanofi Recent Development
11.12 Abbott Laboratories
11.12.1 Abbott Laboratories Company Detail
11.12.2 Abbott Laboratories Business Overview
11.12.3 Abbott Laboratories Rheumatoid Arthritis (RA) Drugs Introduction
11.12.4 Abbott Laboratories Revenue in Rheumatoid Arthritis (RA) Drugs Business (2019-2024)
11.12.5 Abbott Laboratories Recent Development
11.13 Teva Pharmaceutical
11.13.1 Teva Pharmaceutical Company Detail
11.13.2 Teva Pharmaceutical Business Overview
11.13.3 Teva Pharmaceutical Rheumatoid Arthritis (RA) Drugs Introduction
11.13.4 Teva Pharmaceutical Revenue in Rheumatoid Arthritis (RA) Drugs Business (2019-2024)
11.13.5 Teva Pharmaceutical Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

AbbVie
Roche
Merck
HEYL Chemisch-pharmazeutische Fabrik
Johnson & Johnson
Amgen, Inc.
Pfizer
Bristol-Myers Squibb
UCB
GSK
Sanofi
Abbott Laboratories
Teva Pharmaceutical

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.